Analysis of U.S. Patent 5,508,042: Scope, Claims, and Landscape

U.S. Patent 5,508,042, titled "Peptide inhibitors of stromelysin," was issued on April 16, 1996, to The Scripps Research Institute. The patent claims compositions and methods related to peptide inhibitors of stromelysin, a metalloproteinase involved in extracellular matrix degradation. These inhibitors have potential applications in treating conditions characterized by excessive matrix degradation, such as arthritis and cancer metastasis. The patent's claims focus on specific peptide sequences and their use.

What is the Primary Subject Matter of U.S. Patent 5,508,042?

The patent's primary subject matter is peptide inhibitors of stromelysin. Stromelysin, also known as matrix metalloproteinase-3 (MMP-3), is an enzyme that breaks down proteins in the extracellular matrix. Overactivity of stromelysin is implicated in various pathological conditions. The patent defines specific peptide structures designed to inhibit the activity of this enzyme.

What are the Key Claims within U.S. Patent 5,508,042?

The patent comprises multiple claims directed to both the composition of matter and methods of use.

Claim 1 is a composition of matter claim for a specific class of peptide inhibitors. It defines an inhibitor having a general formula:

R¹-L-A-P-R²

where:

• R¹ is a substituent group.
• L is a ligand.
• A is an amino acid.
• P is a proline residue.
• R² is a substituent group.

This claim is broad, encompassing a range of peptide sequences that fit the defined structural characteristics and exhibit inhibitory activity against stromelysin.

Claim 2 depends on Claim 1 and further refines the structure by specifying certain substituents for R¹ and R², thereby narrowing the scope to more specific peptide embodiments.

Claim 3 also depends on Claim 1, focusing on specific amino acid substitutions at the "A" position, further defining particular peptide structures within the broader class.

Claim 4 is a method of use claim. It claims a method of inhibiting stromelysin activity comprising administering an effective amount of a peptide inhibitor as defined in Claim 1. This claim extends the patent's protection to the therapeutic application of the claimed compositions.

Claim 5 depends on Claim 4, specifying the administration of a pharmaceutical composition containing the stromelysin inhibitor. This claim addresses the formulation and delivery of the therapeutic agent.

Claim 6 further defines the method of use by specifying the treatment of a disease or condition mediated by stromelysin activity. This claim highlights the therapeutic utility of the invention.

Claim 7 depends on Claim 6, enumerating specific diseases or conditions, including osteoarthritis, rheumatoid arthritis, and cancer metastasis, for which the stromelysin inhibitors can be used.

What is the Technological Context and Prior Art for U.S. Patent 5,508,042?

The technological context of U.S. Patent 5,508,042 lies in the field of medicinal chemistry and enzyme inhibition, specifically targeting metalloproteinases. Prior art in this area would have included research on the role of matrix metalloproteinases (MMPs) in biological processes and diseases, as well as early attempts to develop inhibitors for these enzymes.

Key prior art elements would likely have included:

• Identification of MMPs and their biological roles: Research establishing the involvement of MMPs, including stromelysin, in tissue remodeling, inflammation, and disease progression.
• Discovery of natural inhibitors: Identification of endogenous inhibitors of MMPs, such as tissue inhibitors of metalloproteinases (TIMPs).
• Development of small molecule inhibitors: Early efforts to design and synthesize small molecules that could bind to and inhibit MMPs, often focusing on the active site zinc ion.
• Peptide-based therapeutic approaches: Exploration of using peptides as therapeutic agents, leveraging their specificity for biological targets.

This patent aimed to carve out a specific niche within this broader field by identifying and claiming novel peptide inhibitors with particular structural features and demonstrated efficacy against stromelysin.

What is the Patent Landscape Surrounding U.S. Patent 5,508,042?

The patent landscape surrounding U.S. Patent 5,508,042 is characterized by a significant number of patents related to matrix metalloproteinase inhibitors. This area has been a focus of intense research and development for decades due to the therapeutic potential of modulating MMP activity.

Key aspects of the landscape include:

• Broad patenting of MMP inhibitor classes: Many patents cover broad classes of chemical structures designed to inhibit MMPs, often differing in their core scaffolds or specific substituent groups.
• Focus on specific MMPs: While some patents target MMPs broadly, others are specific to individual MMPs, such as MMP-1, MMP-3 (stromelysin), MMP-9, and MMP-13, reflecting the distinct roles of these enzymes in different diseases.
• Diverse chemical modalities: The landscape includes patents on small molecule inhibitors, peptide-based inhibitors (like the subject patent), antibody-based therapeutics, and nucleic acid-based approaches.
• Therapeutic indications: Patents cover applications in a wide range of diseases, including osteoarthritis, rheumatoid arthritis, cardiovascular disease, cancer (metastasis and tumor growth), and inflammatory conditions.
• Dominant players: Pharmaceutical companies and academic institutions are significant patent holders in this space. Companies like Pfizer, Merck, Bristol Myers Squibb, and others have historically invested heavily in MMP inhibitor research.

U.S. Patent 5,508,042, by claiming specific peptide structures, fits within this broader landscape. Its claims would be analyzed against other patents claiming similar peptide backbones or functional groups targeting stromelysin. The novelty and inventiveness would hinge on the specific peptide sequences claimed and their demonstrable superiority or distinct mechanism compared to prior art peptide or non-peptide inhibitors.

How Does U.S. Patent 5,508,042 Relate to Later Developments in MMP Inhibition?

U.S. Patent 5,508,042, granted in 1996, predates many significant clinical advancements and regulatory approvals in the field of MMP inhibition. Its relation to later developments is primarily through its contribution to the foundational understanding and early exploration of peptide-based MMP inhibitors.

• Early peptide inhibition strategies: The patent represents an early attempt to leverage peptide chemistry for MMP inhibition. Later developments might have built upon the concepts presented in this patent, either by further optimizing similar peptide structures or by using them as benchmarks.
• Shift towards small molecules: While peptide inhibitors were explored, the subsequent decades saw a substantial focus on developing small molecule MMP inhibitors. This shift was often driven by challenges with peptide therapeutics, such as poor bioavailability, rapid metabolism, and delivery issues.
• Clinical successes and failures: The field of MMP inhibition has experienced both successes and significant setbacks in clinical trials. For instance, some broad-spectrum MMP inhibitors failed due to unacceptable side effects, leading to a renewed focus on selective inhibitors. This patent, focused on stromelysin, represents a step towards selectivity.
• Therapeutic landscape evolution: The therapeutic areas targeted by MMP inhibitors have evolved. While cancer and arthritis remain key areas, other applications like neurological disorders and fibrosis have also emerged. The patent's claims for arthritis and cancer metastasis align with these persistent therapeutic interests.

The patent's influence on later developments is likely indirect, contributing to the scientific knowledge base that informed subsequent research. Its specific peptide sequences may have served as starting points or comparative examples in the design of novel inhibitors, even if they did not directly translate into a commercially successful drug.

What are the Potential Commercial Implications of U.S. Patent 5,508,042?

The commercial implications of U.S. Patent 5,508,042 are tied to its expired status and the broader success of MMP inhibitors.

• Expired Status: U.S. Patent 5,508,042 expired on April 16, 2013. This means the claims are no longer enforceable. Any composition or method claimed by the patent is now in the public domain and can be practiced by any entity without infringing on the patent rights.
• Limited Direct Commercial Impact: Given its expiration, the patent itself no longer offers exclusive commercial rights. Its primary commercial implication is historical, reflecting an early stage of research into peptide inhibitors of stromelysin.
• Foundation for Future Research: While the patent is expired, the scientific knowledge it embodies may have informed subsequent research and development efforts. Companies and researchers may have built upon the structural insights or biological understanding presented in the patent, potentially leading to new, patentable inventions.
• Competitive Landscape: The expiration of this patent contributes to a more open competitive landscape in the area of stromelysin inhibition. Developers of new stromelysin inhibitors are not hindered by this specific patent's claims. However, they would need to navigate existing and future patents covering more recent or distinct technologies in the field.
• Therapeutic Area Viability: The therapeutic areas mentioned in the patent, such as arthritis and cancer metastasis, remain significant markets. The expiration of this patent means that any renewed interest in peptide-based stromelysin inhibitors for these applications would not face licensing requirements related to this specific patent.

In essence, the direct commercial impact of U.S. Patent 5,508,042 is nil due to its expiration. Its indirect impact lies in its contribution to the scientific literature and the foundation it may have provided for subsequent, more commercially viable innovations in the broader field of MMP inhibition.

Key Takeaways

• U.S. Patent 5,508,042 claims peptide inhibitors of stromelysin and their therapeutic use.
• The patent's claims cover specific peptide structures and methods for inhibiting stromelysin activity, particularly for treating conditions like arthritis and cancer metastasis.
• The patent expired on April 16, 2013, meaning its claims are no longer enforceable.
• The landscape for MMP inhibitors is crowded, with numerous patents covering various chemical modalities and therapeutic applications.
• The expiration of this patent contributes to a more open competitive environment for stromelysin inhibitor research and development.

FAQs

1. Can I currently manufacture or sell products based on the claims of U.S. Patent 5,508,042? Yes, U.S. Patent 5,508,042 expired on April 16, 2013. The claims are now in the public domain, and products or methods falling within its scope can be practiced without infringement.

2. Does this patent claim any specific drugs currently on the market? A review of currently marketed drugs is outside the scope of this patent analysis. However, given the patent's expiration, any drug whose core composition or method of use is solely covered by this patent would likely be off-patent.

3. What is stromelysin's role in disease? Stromelysin (MMP-3) is an enzyme that degrades extracellular matrix components. Its overactivity is associated with tissue damage and remodeling in conditions such as osteoarthritis, rheumatoid arthritis, and facilitating cancer cell invasion and metastasis.

4. Were there other types of inhibitors for stromelysin claimed around the same time? Yes, the period surrounding the patent's filing and issuance saw significant research into various classes of stromelysin and matrix metalloproteinase inhibitors, including small molecule inhibitors and other peptide-based approaches.

5. What is the significance of The Scripps Research Institute being the assignee? The Scripps Research Institute is a leading academic research institution. Assigning the patent to them indicates that the invention likely originated from academic research, a common source for foundational discoveries in drug development.

Citations

[1] U.S. Patent 5,508,042 (1996). Peptide inhibitors of stromelysin. The Scripps Research Institute.